Predictors for Risk for Developing Taxane-Induced Peripheral Neuropathy
the Cancer Therapy Advisor take:
Single-nucleotide polymorphisms (SNPs) and genetically determined race were identified as two significant biomarkers associated with predicting taxane-induced peripheral neuropathy (TIPN) in patients, according to an article published online in the journal Clinical Cancer Research.
This genome wide association study (GWAS) included 3,431 patients who were a part of the phase 3 adjuvant breast cancer trial, ECOG-5103. In the trial, genotypes were compared with TIPN.
Top SNPs were evaluated for TIPN as candidate validation in a different phase 3 adjuvant breast cancer trial (ECOG-1199).
Results from ECOG-5103 showed that for grade 3 to 4 TIPN, 120 SNPs were identified for patients of European descent (EA) (P<10-4). In ECOG-1199, 30 candidate SNPs were evaluated, however only SNP rs3125923 was determined to have a significant correlation with grade 3 to 4 TIPN (OR: 1.8; P=1.1 x 10-11).
Furthermore, race was determined to be a significant predictor of TIPN in patients of African descent (AA). These patients were at an increased risk of both grades 2 to 4 and grades 3 to 4 TIPN (HR=2.1; P=5.6×10-16 compared to HR=2.6; P=1.1×10-11, respectively).
A trend toward an association between grades 2 to 4 TIPN and a SNP in FCAMR (rs1856746) was observed in AA patients from ECOG-5103 (OR=5.5; P=1.6 x 10-7).
Single-nucleotide polymorphisms (SNPs) and genetically determined race were identified as two significant biomarkers associated with predicting taxane-induced peripheral neuropathy (TIPN) in patients
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma